ʻO Neuropsychopharmacology. 2017 Jan 4. hana: 10.1038 / npp.2017.1.
Kuiper LB1,2, ʻO Frohmader KS3,4, Coolen LM1,3,4.
Hōʻuluʻulu Manaʻo
ʻO ka hoʻohanaʻana i nā psychostimulants e pili pinepine ana me ka moekolohe, a ua hoʻomaopopo nā poʻe loea i nā hopena o ka lāʻau ma luna o ka moe kolohe e like me ke kumu no ka hoʻohana houʻana. Ua hōʻike muaʻia e hōʻike ana i ka methamphetamine (Meth), i ka manawa e hanaʻia me ka moe kolohe e hōʻike i ka hemahema o ka hōʻeha i ka moekolohe i loko o ke kaʻina o ke kāne (CSA) kahi e pili ana i ka maʻi. He hōʻike kēia i ka moe kolohe ma muli o ka Meth a me kaʻike wahine.
Ua nānāʻia ka haʻawina o kēia manawa i nā ala ala neural i hanaʻia i ka wā o ka hanaʻana i ka moekolohe a me nā hopena o nā Meth e pili like me ka moekolohe ma nā hana kūwaho i kēia mau ala, me ka hoʻohanaʻana i ka ERK phosphorylation (pERK)
ʻO ka mea mua,ʻo kaʻikeʻana i nā kūlana hōʻeuʻeu i nā kāne i aʻoʻia e kāohi i ka moe kolohe i loko o ka māhele CSA, ua hoʻonuiʻia ka'ōlelo PERK ma mua o ka medial forefrontal (mPFC), cortex orbitofrontal (OFC) a me nā wahi o striatum a me amygdala..
ʻO ka lua, nā hopena o nā Meth a me ka wahine e like me ka ho'āʻoʻia i nā kāne i hōʻikeʻia i nā lā a pau o ka Meth (4 mg / kg) o Meth e like me ka hōʻikeʻana iā CSA hoʻokahi pule ma hope o ka hoʻomaʻemaʻe hope. Hōʻike ka Meth a me nā kāne i ke kāne me ka hōʻehaʻole i ka hanaʻana i ka male, ka'ōlelo kiʻekiʻe kiʻekiʻe ma lalo o nā kumu papahana, a hoʻopauʻia ka pERK induction ma muli o ka hopena o nā hanu i loko o mPFC a me OFC.
ʻO nā hoʻololiʻana o ka PERK i CaMKII-e hōʻike ana i nā neurones, e manaʻo ana e hoʻololi i nā'ōkuhi o kēia mau wahi. Ma kēia mau hōʻike, hōʻikeʻia kēiaʻikeʻike Meth a me ka pilina e pili ana i ka hana kolohe e pili ana i nā hoʻololiʻana i ka hoʻokumuʻana i nā neural i mPFC a me OFC.
PMID: 28051103
DOI: 10.1038 / npp.2017.1
;